



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

To,
The Listing Department,
BSE Ltd.

May 22, 2019

Sub: Outcome of Board Meeting held on May 22, 2019.

We wish to inform you that the Board Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses:

1. Appointed Dr. Yogeswara Rao Danda (DIN 00694803) as Additional Director (Independent Category) w.e.f May 22, 2019 - Brief profile of Dr. Yogeswara Rao Danda is enclosed
2. Took note of resignation of Dr. Jang Bahadur Gupta (DIN 07751205) as Independent Director - Dr. Jang Bahadur Gupta has submitted his resignation as Independent Director w.e.f May 22, 2019 due to his pre-occupation.
3. Reconstituted the Audit Committee, Stakeholders Relationship Committee and Nomination & Remuneration Committee
4. Approved the audited standalone financials for the half year and year ended March 31, 2019 and took note of the Auditors Report thereon
5. Approved the audited consolidated financials for the half year and year ended March 31, 2019 and took note of the Auditors Report thereon

Please find enclosed standalone and consolidated financial results for half year and year ended March 31, 2019 along with the Auditors Report issued by the statutory auditors of the Company.

Further, in compliance with Regulation 33 of Listing Regulations, the Board hereby declares/certifies that the statutory auditors of the Company have submitted their Audit Report on the standalone and consolidated financial results of the Company for the FY 2018-19 with an unmodified and unqualified opinion.






Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

We hereby submit that there is no deviation or variation in the use of proceeds of public issue and Preferential Issue from the objects as stated in the prospectus dated September 01, 2017 and explanatory statement of Notice of EGM held on September 29, 2018 respectively. Kindly refer Notes to the standalone and consolidated financial statements for category wise details of projected utilization and actual utilization of proceeds from Public Issue and Preferential Allotment. The said has also been taken note by the Audit Committee and the Board in their meeting held today – May 22, 2019.

The meeting commenced at 11.30 A.M. and concluded at 7.30 P.M.

This for your information and dissemination to the public.

For VANTA BIOSCIENCE LIMITED

Scrip Code: 540729 | Scrip ID: VANTABIO

A handwritten signature in blue ink, appearing to read 'Dopesha Raja', is written over the stamp.



DOPESH RAJA MULAKALA
MANAGING DIRECTOR
DIN: 01176660



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

Brief Profile of Dr. Yogeswara Rao Danda

Dr. D. Yogeswara Rao is currently a visiting professor at University of Hyderabad, Hyderabad for Innovation and entrepreneurship. He is also a consultant to CSIR-IICT. He served as Adviser at the office of Principal scientific Adviser to Government of India, New Delhi before superannuation. Previous to that, he served Council of Scientific and Industrial Research (CSIR) for over 25 years in different capacities. He has a Masters' degree in Chemistry from Andhra University and Ph.D degree from Indian Institute of technology, Bombay in chemistry. Before joining CSIR in 1988 he worked with industry for over six and half years.

Dr. Rao has been associated with Science, Technology and Innovation for large part of his career, besides encouraging knowledge-based entrepreneurship. He has expertise lies in R&D management with interests in R&D Planning, Technology assessment, transfer and entrepreneurship, besides organisational policies. He specializes in building multi-institutional and industry network projects.

He has been appointed as an Independent Director and is not associated with any other Director of the Company in any way.






Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
 Rasoolpura, Secunderabad - 500 003, INDIA.
 Tel : +91 40 6657 5454, 2790 3226
 Fax : +91 40 2790 8708
 Website : www.vantabio.com
 Email : info@vantabio.com
 CIN No. : L74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003
CIN L74999TG2016PLC109280

(Rs.in Lakhs)

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED 31st MARCH 2019

Sr.No	Particulars	STANDALONE				
		6 MONTH ENDED			YEAR ENDED	
		31.03.2019 (Audited)	30.09.2018 (Un Audited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
1	Income					
	Revenue from Operation	640.26	602.22	349.25	1242.48	398.6
	Other Income	15.32	7.56	5.28	22.88	5.28
	Total Revenue	655.58	609.78	354.53	1265.36	403.88
2	Expenses					
	a) Cost of material Consumed	63.91	75.89	27.64	139.8	32.26
	b) Employee Benfit Expenses	234.01	181.38	149.31	415.39	161.11
	c) Financial Cost	89.53	79.32	15.8	168.85	19.64
	d) Depreciation and amortization Exp	34.80	36.29	40.84	71.09	57.22
	e) other expenses	169.40	191.07	95.73	360.47	102.15
	Total Expenses	591.65	563.95	329.32	1155.6	372.38
3	Profit/(Loss) from ordinary activities before Exceptional Items (1-2)	63.93	45.83	25.21	109.76	31.5
4	Exceptional Items Income /(Expenses)	0	0	0	0	0
5	Profit/(Loss) from ordinary activities before tax (3+4)	63.93	45.83	25.21	109.76	31.5
6	Tax Expenses					
	a) Current Tax	14.07	8.82	6	22.89	6.00
	b) Deferred Tax	9.78	7.71	21.57	17.49	22.77
7	Net Profit/(Loss) from ordinary activities after tax (5-6)	40.08	29.30	-2.36	69.38	2.73
8	Other Comprehensive Income / (expenses) for the year, net of tax	0	0		0	0
9	Total Comprehensive Income/(Loss) Net of Tax (6+8)	40.08	29.30	-2.36	69.38	2.73
10	Paid up Equity share capital (face value of Rs.10/-)	631.20	572.80		631.20	572.80
11	Reserve excluding Revaluation reserve					
12	Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised)					
	a) Basic (Rs.)	0.77	0.51	0	1.17	0.05
	b) Diluted (Rs.)	0.77	0.51	0	1.17	0.05
	Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised)					
	a) Basic (Rs.)	0.77	0.51	0	1.17	0.05
	b) Diluted (Rs.)	0.77	0.51	0	1.17	0.05

For and on behalf of Board of Directors

Dopesh Raja Mulakala
 Managing Director



Place : Hyderabad
 Date : 22.05.2019



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003
CIN L74999TG2016PLC109280

(Rs.in Lakhs)

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE HALF YEAR AND YEAR ENDED 31st MARCH 2019

Sr.No	Particulars	CONSOLIDATED			
		6 MONTH ENDED		YEAR ENDED	
		31.03.2019	30.09.2018	31.03.2019	31.03.2018
1	Income				
	Revenue from Operation	646.06	602.22	1248.28	398.60
	Other Income	15.40	7.56	22.96	5.28
	Total Revenue	661.455	609.78	1271.235	403.88
2	Expenses				
	a) Cost of material Consumed	63.91	75.89	139.80	32.26
	b) Employee Benfit Expenses	234.01	181.38	415.39	161.11
	c) Financial Cost	89.57	79.32	168.89	19.64
	d) Depreciation and amortization Exp	34.80	36.29	71.09	57.22
	e) other expenses	174.87	191.07	365.94	102.15
	Total Expenses	597.1612	563.95	1161.1112	372.38
3	Profit/(Loss) from ordinary activities before Exceptional Items (1-2)	64.2938	45.83	110.1238	31.5
4	Exceptional Items Income /(Expenses)	0	0	0	0
5	Profit/(Loss) from ordinary activities before tax (3+4)	64.2938	45.83	110.1238	31.5
6	Tax Expenses				
	a) Current Tax	14.16	8.82	22.98	6.00
	b) Deferred Tax	9.78	7.71	17.49	22.77
7	Net Profit/(Loss) from ordinary activities after tax (5-6)	40.35	29.30	69.65	2.73
8	Other Comprehensive Income / (expenses) for the year, net of tax	0	0	0	0
9	Net Comprehensive Income/(Loss) Net of Tax (7+8)	40.35	29.30	69.65	2.73
10	Paid up Equity share capital (face value of Rs.10/-)	631.20	572.80	631.20	572.80
11	Reserve excluding Revaluation reserve				
12	Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.78	0.51	1.19	0.05
	b) Diluted (Rs.)	0.78	0.51	1.19	0.05
	Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.78	0.51	1.19	0.05
	b) Diluted (Rs.)	0.78	0.51	1.19	0.05

For and on behalf of Board of Directors

Dopesh Raja Mulakala

Managing Director

DIN:01176660



Place : Hyderabad
Date : 22.05.2019



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.

Tel : +91 40 6657 5454, 2790 3226

Fax : +91 40 2790 8708

Website : www.vantabio.com

Email : info@vantabio.com

CIN No. : U74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF ASSETS & LIABILITIES AS ON 31st MARCH 2019					
Sr.No.	Particulars	STANDALONE		CONSOLIDATED	
		31.03.2019	31.03.2018	31.03.2019	31.03.2018
		Audited	Audited	Audited	Audited
A	Equity and Liabilities				
1	EQUITY				
	a) Equity share capital	631.20	572.80	631.20	572.80
	b) Reserve & Surplus	1593.30	1085.93	1593.57	1085.93
	c) Non Controlling/Minority Interest	0.00	0.00	0.00	0.00
	Sub total Equity	2224.50	1658.73	2224.77	1658.73
	LIABILITIES				
2	Non Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	1216.63	998.00	1266.61	998.00
	b) Provisions	0.00	0.00	0.00	0.00
	c) Deferred tax Liabilities	40.26	22.77	40.26	22.77
	d) Other Non Current Liabilities	0.00	0.00	3.54	0.00
	Sub Total -Non Current Liabilities	1256.89	1020.77	1310.41	1020.77
3	Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	0.00	49.85	0.00	49.85
	ii) Trade Payables	45.73	19.43	45.73	19.43
	b) Other Current Liabilities	260.99	164.34	260.99	164.34
	c) Provisions	12.17	2.98	14.32	2.98
	d) Current tax Liabilities(net)	0.00	0.00	0.00	0.00
	Sub Total -Non Current Liabilities	318.89	236.60	321.04	236.60
	Total Equity and Liabilities	3800.28	2916.10	3856.23	2916.10
B	ASSETS				
1	Non Current Assets				
	a) Property, Plant and Equipment	1303.75	1262.94	1303.75	1262.94
	b) Capital Work in Progress	369.84	234.16	369.84	234.16
	c) Other Intangible assets	486.23	486.23	486.23	486.23
	d) Other intangible assets under development	0.00	0.00	0.00	0.00
	e) Investment in associates and joint ventures	0.00	0.00	0.00	0.00
	f) Financial Assets	0.00	0.00	0.00	0.00
	i) Investments in Subsidiary	199.99	0.00	0.00	0.00
	ii) Loans	0.00	0.00	98.00	0.00
	iii) Other Financial Assets	0.00	0.00	0.00	0.00
	g) Deferred tax assets (net)	0.00	0.00	0.00	0.00
	h) Other non current assets	35.04	35.04	35.04	35.04
	Sub Total Non-CurrentAssets	2394.85	2018.37	2292.86	2018.37
2	Current Assets				
	a) Inventories	924.42	302.44	924.42	302.44
	b) Financial Assets			0.00	
	i) Investments	195.00	450.00	195.00	450.00
	ii) Trade Receivable	156.40	33.02	161.56	33.02
	iii) Bank, Cash and Cash equivalents	28.43	8.74	180.55	8.74
	iv) Loans & Advances	89.62	51.73	90.04	51.73
	iv) Othe Financial Assets	0.00	0.00	0.00	0.00
	c) Current Tax Assets (net)	0.00	0.00	0.00	0.00
	d) Other Current Assets	11.56	51.80	11.79	51.80
	Sub Total Current Assets	1405.43	897.73	1563.37	897.73
	Total Assets	3800.28	2916.10	3856.23	2916.10

For and on behalf of Board of Directors

Place : Hyderabad

Date : 22.05.2019

Dopesh Raja Mulakala

Managing Director

DIN:01176660

Research Center:

K2-B, 11th Cross Street, SIPCOT Industrial Complex,
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.

Tel : 044 6790 1600

Notes to Standalone and consolidated financial statements:

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 22nd May, 2019.
2. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND-AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
3. Statement of Assets and Liabilities as on 31st March, 2019 is enclosed herewith
4. There were no investor complaints received/pending as at 31st March, 2019.
5. The financial figures for the previous half year/year have been regrouped/reclassified, Wherever necessary to confirm to current period.
6. We hereby inform that there was no deviation in the utilization of proceeds as stated in the objects of prospectus of the public issue and explanatory statement of the EGM notice. The utilization statement as stated below

(Amount In Lakhs)

Public Issue Proceeds	Projected	Actual Utilization
Working Capital	679.40	679.40
General Corporate & Working Capital	26.60	26.60
Public issue Expenses	50.00	50.00
Total	756.00	756.00

The Company during the year issued 5,84,000 equity shares of Rs. 10/- each at a premium of Rs. 75/- on preferential basis and their utilization is as follows:

(Amount In Lakhs)

Proceeds from Preferential Allotment	496.40
Utilization	
Investment in Subsidiary	200.00
General Corporate & Working Capital	76.40
Issue Expenses	25.00
Balance - Investment in liquid funds	195.00
Total	496.40

7. The statement includes figures of half year ended March 31, 2019 being the balancing figure between the audited figures in respect of the full financial year and the unaudited figures of the previous half year.



8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
9. During the year Company incorporated a fully owned subsidiary in the name and style of Vanta Clinical Research Limited on Dt.12/09/2018. Under this subsidiary, Company will carry out the business of Clinical Research viz., Bio equivalence, Bio Analytical studies, Phase studies (1-IV), and Pharmacovigilance and Medical Writing activities. The Company also incorporated step down subsidiary on 10th October,2018 as Vayam Research Solutions Limited to carry out the clinical Business.
10. The Statutory auditor have expressed an un modified opinion on the standalone and consolidated Financial statements
11. The said results are uploaded on the website of the Company www.vantabio.com and on BSE Ltd.





MATHESH & RAMANA
CHARTERED ACCOUNTANTS

To
Board of Directors of
M/s. VANTA BIOSCIENCE LIMITED
(CIN: L74999TG2016PLC109280)

We have audited the financial results of **VANTA BIOSCIENCE LIMITED** for the half year ended 31.03.2019 and the year to date results for the period 01.04.2018 to 31.03.2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These Half yearly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.


In our opinion and to the best of our information and according to the explanations given to us These Half yearly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;
And
- ii. give a true and fair view of the net profit and other financial information for the Half year ended 31.03.2019 as well as the year to date results for the period from 01.04.2018 to 31.03.2019

Place: Hyderabad
Date: 22nd May, 2019



For Mathesh & Ramana,
Chartered Accountants,


B.V. Ramana Reddy
Partner

Membership No.026967

E-mail : matheshca@yahoo.co.in

3-6-145, Himayatnagar, Hyderabad - 500 029, Ph: 2322 1822 / 2322 6993 / 2322 2863



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

To
The Board of Directors of
M/s. VANTA BIOSCIENCE LIMITED
(CIN: L74999TG2016PLC109280)
Hyderabad

1. We have audited the accompanying Statement of Consolidated Financial Results of VANTA BIOSCIENCE LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of for the year ended 31.03.2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding half year ended 31.03.2019, as reported in these financial results have been audited by the other auditors and approved by the Parent's Board of Directors.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.
3. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act 2013. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Parent's internal financial control with reference to the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



E-mail : mateshca@yahoo.co.in

3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

We believe that the audit evidence obtained by us and the audit evidence obtained by the Subsidiary company auditors in terms of their reports referred to in paragraph 5 below, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, in paragraph 5 below, the Statement:

a. includes the results of the following entities:

List of Subsidiaries:

Vanta Clinical Research Limited
Vayam Research solutions Limited (Step Subsidiary)

b. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

c. gives a true and fair view in conformity with the recognition and measurement principles Laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated total comprehensive Income

5. The financial statements of two subsidiaries included in the consolidated financial results whose financial statements reflect total assets of Rs. 506.17 lacs as at 31.03.2019 and total revenues of Rs.08.80 lacs, total net profit after tax of Rs. 0.41 lacs for the year ended on that date, as considered in the consolidated financial statements. These financial statements have been audited by the other auditors whose reports have been furnished to us by the management, and in our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our opinion on the Statement is not modified in respect of the above matters.

6. The statement includes the results for the half year ended 31.03.2019 being the balancing figure between audited figures in respect of the full financial year and the published audited year to date figures up to the first half year of the current financial year.

Place: Hyderabad
Date: 22nd May, 2019



For Mathesh & Ramana.,
Chartered Accountants,


B.V. Ramana Reddy
Partner

Membership No.026967